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Abstract
Background: To reduce the risk of brain damage children with acute lymphoblastic leukaemia
(ALL) are nowadays mainly treated with intrathecal chemotherapy (ITC) instead of central nervous
system (CNS) radiation therapy (CRT) to prevent CNS relapse. However, chemotherapy may also
lead to cognitive deficits. As growth hormone deficiency (GHD) or impaired growth hormone
secretion are frequently found in ALL patients treated with cranial radiation therapy and/or
chemotherapy, we hypothesized that GH therapy may reduce cognitive deficits in these patients.
Methods: Twenty young adult survivors of childhood ALL with reduced bone mineral density (<-
1 SD) and/or low IGF-I SD-scores (<-1 SD) were included in the study. A final group of 13 patients
(9 males and 4 females), mean age 23.7 ± 2.9 years (range 20 – 29.7) completed a 2-year treatment
with GH.
IQ and neuropsychological performance were assessed at pre-treatment (T1) and after one (T2)
and two (T3) years. ANOVA was performed with assessment at T1, T2 and T3 as repeated
measurements factor. Relations between test score changes and changes of IGF-I levels were
determined by calculating the Pearson correlation coefficient.
Results: Scores on the cognitive tests were in the normal range. Verbal short- and long-term
memory performance decreased between T1 and T2, and increased between T2 and T3.
Performance at T3 was not significantly different from that at T1. Performance for sustained
attention improved from T1 to T2 and from T1 to T3. Visual-spatial memory was improved after
one year of GH treatment. A significant positive correlation was found for Δ IGF-I (T2-T1) with
difference scores of visual-spatial memory (T2-T1 and T3-T1), indicating that IGF-I increase after
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one year of GH treatment is associated with increase in cognitive-perceptual performance at
month 12 and 24.
Conclusion: Since the level of intellectual functioning of our patient cohort was in the normal
range the present finding that GH treatment has negative effects on verbal memory and positive
on attention and visual-spatial memory warrants similar studies in other groups of ALL survivors.
Also, a lower dose of GH should be determined inducing as much IGF as needed to improve verbal
as well as visual cognitive functions. The present findings indicate that more knowledge is needed
before GH treatment may be recommended to enhance cognitive functions in ALL survivors.
Background
In the last decades the prognosis of children with acute
lymphoblastic leukaemia (ALL) has improved dramati-
cally and long-term survival rates up to 80% have been
reported [1]. Along with this development much research
has been directed at identifying the psychological effects
of treatment for ALL in childhood, in particular the neu-
ropsychological sequelae. Prophylactic intrathecal (IT)
chemotherapy (ITC) has replaced CNS radiation therapy
(CRT), as research revealed cognitive deterioration and
deficits associated with such CRT [2,3]. However, negative
effects of high-dose IT chemotherapy regimens have been
reported. For instance, children with ALL who had
received chemotherapy for 3 years were more impaired on
neurocognitive tasks involving right hemisphere simulta-
neous processing than their healthy siblings and than ALL
children diagnosed recently or receiving chemotherapy
for one year [4]. From a study by Copeland et al. [5] the
cognitive side effects of IT chemotherapy appeared to be
slightly more apparent 5 to 11 years after diagnosis than
at 3-year follow-up. Since the differences were not clini-
cally meaningful, the effects of chemotherapy in the
absence of CRT were concluded to be slight. This is in
accordance with the finding that the intellectual perform-
ance of survivors of paediatric ALL (age 6.8–33.7 years)
treated with chemotherapy was normal [6]. In contrast,
from thirty three reviewed studies on the long-term conse-
quences of CNS chemotherapy in ALL survivors approxi-
mately two thirds document a decline in cognitive
abilities [7]. For instance, patients treated with chemo-
therapy showed worse memory and fine-motor functions,
but not school level, than their siblings [8]. Recently,
behavior problems but also poor school performance was
found in children with ALL attending primary school
compared with same-age peers, although the rate of utili-
zation of special education services was low. Thus, treat-
ment for childhood ALL with chemotherapy may be
associated with subtle but significant behavioral and edu-
cational problems [9].
Indeed, as with CRT, there is evidence that systemic CNS-
directed and IT chemotherapy may lead to brain abnor-
malities, such as decreased cerebral perfusion, slower rest-
ing electroencephalogram frequencies, white matter
changes and enlargement of the ventricles and cortical
sulci [7].
From the studies cited above it may be concluded that
cognitive impairment may be present in children with
ALL who have been treated with CRT or IT chemotherapy.
Therefore, a number of approaches to remediate these def-
icits, such as cognitive remediation, pharmacology and
ecological alterations in the classroom, have been pro-
posed. With respect to pharmacotherapy, in particular the
use of phenylphenidate seems to be encouraging for ALL
survivors with learning and attention problems [10].
Another pharmacological approach may be the use of
growth hormone (GH) treatment. Growth hormone defi-
ciency (GHD) or impaired GH secretion are frequently
found late effects in patients treated with cranial radiation
therapy and/or chemotherapy for childhood ALL [11-13].
Cognitive functioning and IQ appears subnormal in
patients with GHD, as patients complain of lapses of
attention, difficulty in concentrating, and forgetfulness.
Moreover, their IQ score and educational level appear to
be positively related to the concentration of insulin-like
growth factor I (IGF-I), a serum marker for GH status, sug-
gesting that subnormal cognitive performance is specifi-
cally related to GHD [14,15]. The association between
cognitive functions and GH may be explained by the pres-
ence of many binding sites of GH and IGF-I in the hippoc-
ampus, a brain structure that is important for learning and
memory functions [16]. Some studies suggest that GH
therapy can have beneficial effects for the cognitive func-
tioning of GH deficient adults, in particular memory func-
tion [17] and attention [18,19]. The psychological effects
of GH therapy in a group of survivors of childhood cancer
have been investigated only once before. However, aim of
that study was to establish health related Quality of Life of
survivors (most of them ALL), whether or not with GHD
requiring GH treatment, while effects on neurocognitive
functioning were not studied [20].
The present study is the first that evaluated the effects of
GH on neurocognitive functioning of ALL survivors with
a low bone mass and/or low IGF-I levels. We hypothe-BMC Pediatrics 2008, 8:25 http://www.biomedcentral.com/1471-2431/8/25
Page 3 of 8
(page number not for citation purposes)
sized that GH therapy would show positive effects on neu-
rocognitive functioning, in particular attention and
memory, in adult survivors of paediatric ALL.
Methods
Patients
Young adult survivors of childhood leukaemia with
reduced bone mineral density (<-1 SD) and/or low IGF-I
SD-scores (<-1 SD) were selected from a group of patients,
treated for ALL between 1972 and 1990 at the paediatric
departments of the VU University Medical Center and the
Academic Medical Center in Amsterdam. The inclusion
criteria were chosen like this because originally the study
was designed to see whether bone mineral density would
improve after GH intervention. Twenty out of 56 (36%)
childhood ALL survivors over 20 years of age were
included according to these criteria. These patients had
never been tested for GHD and as a consequence were
never treated with GH before.
Treatment of ALL had been given according to different
treatment protocols. In general, treatment consisted of an
intensive induction period, followed by a 2 to 3 year
maintenance period. All patients received systemic cyto-
static treatment, including corticosteroids, vincristine,
methotrexate and 6-mercaptopurine and sometimes other
cytostatic drugs were added. In addition, 17 patients out
of the 20 included received prophylactic cranial irradia-
tion in doses varying from 2000 to 2500 cGy. Three
patients received high-dose methotrexate and intrathecal
chemotherapy (methrotrexate, cytosine-arabinoside,
prednison) instead of cranial irradiation to prevent cen-
tral nervous system relapse.
ALL survivors were reviewed for age at diagnosis, treat-
ment protocol, dose of irradiation, and time elapsed since
irradiation. After an overnight fast a physical examination
was performed and a blood sample was taken to assess
IGF-I serum values. Blood samples were taken and IGF-I
determined at baseline and at month 3, 6, 9, 12, 15, 18,
21 and 24. Mean IGF-I z-scores are shown in Fig. 1. Serum
IGF-I was measured (in duplicate) after extraction by
immunoradiometric assay (DSL, Webster, Texas USA). In
addition, a provocative GH test was performed after over-
night fast in all participants, using growth hormone
releasing hormone in a dose of 100 μg intravenously
(GHRH-test). To assess GH levels, blood samples were
drawn at -15, 0, 10, 20, 30, 45, 60 and 90 minutes. The
subjects rested during the test.
At another morning the insulin tolerance test (ITT) was
carried out in the ALL survivors. Intravenous soluble insu-
lin (Velosulin) was administered in a dose of 0.1 IE insu-
lin/kg body weight. To assess GH levels, blood samples
were taken at -15, 0, 10, 20, 30, 45, 60 and 90 minutes.
During the ITT all subjects achieved blood glucose levels
of < 2.0 mmol/l and there were clinical symptoms of
hypoglycaemia as well. Blood glucose levels were meas-
ured every five minutes during the test.
The study protocol has been approved by the Medical
Committee of Ethics on Human Research of the VU Uni-
versity Medical Centre and written informed consent was
obtained from all patients.
Procedure
Diagnosis of GH deficiency
The diagnosis of GHD was based on a GH peak response
less than 9.0 mU/L (3 microgram/l) in both provocative
tests. Four patients showed a GH peak response below 9.0
mU/L (3 microgram/l) for the ITT, but not for the GHRH-
test; those patients were also considered growth hormone
deficient. In this way, 13 out of 20 patients were GHD.
Serum GH was measured in duplicate by immunometric
assay (Sorin Biomedica, Saluggia Italy). The standards
used were calibrated against the 1st IS 80/505 reference
preparation.
Growth hormone therapy
Of the 20 ALL survivors with decreased BMD and/or IGF-
I, three patients did not start with GH, because one of
them was diagnosed with anorexia nervosa and the other
two refused treatment. The remaining 17 patients started
with GH-therapy for a two-year period (10 males, 7
females; mean age ± SD, 24.4 ± 3.3; range 20 – 31 yrs).
Four patients stopped GH-therapy: two of them got preg-
nant within 3 months, one patient turned out to be
growth hormone resistant and the other stopped for
unknown reasons. A final group of thirteen participants (9
males and 4 females) completed the study. These partici-
pants were treated with growth hormone during 2 years.
Mean IGF-I levels (+ SE) at baseline (T1) and after 3, 6, 9, 12  (T2), 15, 18, 21 and 24 (T3) months of GH therapy Figure 1
Mean IGF-1 Z-score at baseline (T1) and after 3, 6, 9, 
12 (T2), 15, 18, 21 and 24 (T3) months of GH ther-
apy.
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Four of them were not GHD (GH peak response in ITT
between 11.0 and 70.0 mU/l). Mean age at diagnosis was
7.0 ± 4.3 years (range 2.5 – 15.2 years). Mean age at the
start of the study was 23.7 ± 2.9 years (range 20 – 29.7
years). Mean IGF-1 (± SD) at the start of the study was
17.5 ± 5.3, and for IGF-Z-scores it was -1.3 ± 0.6 SD.
All patients used Humatrope subcutaneously with the Eli
Lilly penfill system. The starting dose of GH was calcu-
lated as 0.1 mg per square meters of body surface. Every 2
weeks, the dose was increased with 0.1 mg/m2, until IGF-
I rised above 0 SD. The GH dose that was needed to reach
a level of IGF-1 of +1 SD according to sex and age was very
different per individual. In the first 3 months, patients
were seen after 2, 4, 8 and 12 weeks, after that every 3
months.
Assessment of (neuro)psychological functions
Participants were tested 3 times: before the start of GH
treatment (T1) and after 1 and 2 years of treatment (T2,
T3). Assessments were carried out by a well-trained and
qualified test-assistant. All tests employed were standard-
ized and do have documented data about reliability and
validity.
Intelligence (assessment at T1)
Patients' IQ score (Full scale (FS)IQ, Performal (P)IQ and
Verbal (V)IQ) was assessed only at T1 with the Dutch ver-
sion of the Wechsler Adult Intelligence Scale (W.A.I.S.)
[21].
Memory (assessments at T1, T2, T3)
- 15 Word Test. Auditory verbal learning was tested in two
conditions: immediate recall and recall after a 20-minute
delay [22]. Two comparable versions were used (A at T1
and T3; B at T2) in order to minimize test-retest effects.
- Benton Visual Retention Test. In this test geometrical fig-
ures are presented and have to be recalled immediately by
drawing. The test assesses visual memory, visual percep-
tion and visual-constructional capacities [23].
- Digit Span (subtest of WAIS). Digits are presented ver-
bally and have to be recalled forward or reversed. Span of
immediate verbal recall is tested.
- Rey-Osterrieth Complex Figure Test. After copy drawing of
a complex geometrical figure subjects are asked to recall
this drawing after 20 minutes. Visual-spatial memory is
assessed [24]. To avoid test-retest effects we used two dif-
ferent figures: the Rey-Osterrieth figure at T1 and T3, and
the Taylor figure at T2.
Attention (assessments at T1, T2, T3)
- Fepsy (Auditory Reaction Time) [25]. Auditory reaction
time was assessed with the Auditory Reaction Time
subtest, part of the Fepsy, a Dutch automated computer-
ized test for cognitive functions. In this task the computer
generates a 800 HZ auditory stimulus and the subject has
to produce as quick as possible a push-button response.
Reaction time for the dominant and the non-dominant
hands are measured.
-The Brickenkamp d2 test measuring sustained attention. In
this test a person is asked to detect and encircle correct let-
ter-quotation mark-combinations. Total score is the
number of correctly encircled letters minus the number of
incorrect responses [26].
Executive functions (assessments at T1, T2, T3)
- Trailmaking Test (A and B). Encircled numbers have to be
connected consecutively by drawing lines (part A), or
encircled letters and numbers have to be connected con-
secutively by alternating letters and numbers (part B). This
test examines visual conceptual and visuomotor tracking
[27].
Data analysis
Scores at T1 were compared to test norms (independent
samples test). Statistical analysis comprised analyses of
variance (ANOVA) and correlation analyses. To determine
the effects of GH therapy ANOVA was used with assess-
ment at T1, T2 and T3 as repeated measurements factor. If
the factor assessment yielded significant main effects
within-subjects contrasts were evaluated. To determine
relations between test score changes and changes of IGF-I
levels the Pearson correlation coefficient was calculated.
Significance level was defined as p ≤ .05 (one-tailed). Data
were analysed using the SPSS version 11 software package
(SPSS inc., Chicago, USA).
Results
Table 1 presents test scores prior to the start of GH treat-
ment. The level of intellectual functioning (FSIQ, VIQ,
PIQ) of the group survivors was high average. Memory
tasks all resulted in test scores in the normal range of the
population norms. Visual construction and visual motor
tracking scores also were average in comparison to test
norms. Sustained attention scores and auditory reaction
time (dominant and non-dominant hand) were in the
normal range as well.
Changes in IGF-I Z-score levels across the treatment
period are presented in Fig. 1. Levels at T2 and T3 were sig-
nificantly higher than at baseline (F(1,12) = 39.1, p  ≤
.0005, η2 = 0.76 and F(1,24) = 29.5, p ≤ .0005, η2 = 0.71,
respectively). A significant decrease in IGF-I was seen
between T2 and T3 (F(12,24) = 4.6, p = 0.05, η2 = 0.28).BMC Pediatrics 2008, 8:25 http://www.biomedcentral.com/1471-2431/8/25
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ANOVA showed significant differences between test ses-
sions for Verbal short term memory (STM), Verbal long
term memory (LTM), Visual-spatial long term memory
and Sustained attention (see Table 2).
With respect to verbal short- and long-term memory a sig-
nificant decrease in performance is seen between T1 and
T2, followed by an increase between T2 and T3. The per-
formance on verbal STM and verbal LTM is not signifi-
cantly different between T1 and T3. As is clearly depicted
in Fig. 2, the increase in IGF-I between T1 and T2 is
accompanied by a decrease in short-term memory per-
formance, while the decrease in IGF-I between T2 and T3
is accompanied by an increase in short-term memory
scores. Exactly the same association with IGF-I was found
for long-term memory.
Results for visual-spatial long term memory show an
increase between T1 and T2 followed by a decrease
between T2 and T3 (see table 2). The performance for vis-
ual-spatial long term memory at T3 only tends to be
higher than at T1 (p = 0.07). An increase in performance
for sustained attention is seen between T1 and T2. In addi-
tion, the performance at T3 is significantly better than at
T1 (p < 0.002, see table 2).
As IGF-I levels were higher at T2 and T3 than at baseline
we calculated the correlation between T2-T1 and T3-T1
difference scores of IGF-I and cognitive test scores. Signif-
icant positive correlations were only found of Δ IGF-I (T2-
T1) with Δ visual-spatial long term memory (T2-T1) and
with Δ visual-spatial long term memory (T3-T1) (r = 0.58,
p = 0.02 and r = 0.53, p = 0.04, respectively). This means
that IGF-I increase after one year of GH treatment is asso-
ciated with increase in cognitive performance at month 12
and 24 relative to baseline. There was no correlation
between Δ IGF-I (T3-T1) with Δ visual-spatial long term
memory (T3-T1).
Discussion
In literature the neurocognitive late effects of the treat-
ment of childhood leukaemia have been studied exten-
sively. Deleterious effects of treatment regimens including
cranial radiation in particular have been documented.
Results of studies on the effects of prophylactic CNS treat-
ment with high-dose and intrathecal chemotherapy how-
ever show that such therapy also may have deleterious
effects. Key question in the present study was whether GH
treatment improves neurocognitive functioning of adult
survivors of childhood leukemia. We hypothesized posi-
tive effects of GH treatment, in particular improvement of
attention and memory, based on effect studies in growth
hormone deficient adults [17-19].
In the present study a group of 13 young adult survivors
of childhood leukaemia was assessed neuropsychologi-
cally before and during GH therapy installed because of
decreased BMD and/or too low IGF-I. Most persons (10 of
13) had been treated with regimens including prophylac-
tic cranial irradiation. Many years after treatment (mean
time since diagnosis approximately 15 years) these survi-
Table 2: Mean cognitive scores ± SD and significance levels of factor Session
Session p-value (session)
1 2 3 1–2 2–3 1–3
Verbal short-term memory 46 ± 3.8 40 ± 9.5 49 ± 6.9 0.03 0.000 0.14
Verbal long-term memory 9.2 ± 1.8 6.4 ± 3.0 9.6 ± 2.8 0.008 0.000 0.41
Visual-spatial long-term memory 22.8 ± 6.3 28.2 ± 4.5 26.0 ± 3.9 0.004 0.05 0.07
Sustained attention 378 ± 89 421 ± 100 435 ± 102 0.02 0.45 <0.002
Higher test scores indicate better performance
Table 1: Mean pre-treatment (T1) scores ± SD of ALL survivors 
(n = 13)
Full scale IQ 112 ± 12
Verbal IQ 110 ± 13
Performal IQ 113 ± 13 High average
Verbal short term memory
15 Word Test (number correct) 45.8 ± 3.8 Average
Verbal long term memory
15 Word Test Recall (number correct) 9.2 ± 1.8 Average
Visual-spatial short term memory
Benton (number correct) 8.2 ± 1.8 Average
Short tem memory
Digit Span (WAIS) (number correct) 7.8 ± 3.6 High average
Visual-spatial construction ability
Rey (copy) (number correct) 34.92 ± 1.5
Rey (LTM)(number correct) 22.8 ± 6.3 Average
Auditory RT
Fepsy dominant hand (ms) 242 ± 54.6
Fepsy non-dominant hand (ms) 239 ± 56.9 Average
sustained attention
D2 (number correct) 378 ± 88.7 Average
Visual scanning and tracking
Trailmaking A (sec) 30.8 ± 10.9
Trailmaking B (sec) 61 ± 16.9 Average
Mean scores at T1 ± SD; mean IQ = 100, SD = 15; higher test scores 
indicate better performance except scores in time (Auditory RT and 
Visual Scanning)BMC Pediatrics 2008, 8:25 http://www.biomedcentral.com/1471-2431/8/25
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vors showed test scores on a variety of neuropsychological
tasks in the normal range. Mean level of intellectual func-
tioning as determined by IQ tests was even high average.
This level is higher than expected, since most participants
received prophylactic cranial irradiation as part of their
ALL-treatments. The same holds for the test scores relating
to specific neurocognitive functions we measured. Among
others deficits in memory, visuospatial/motor skills and
attention have been reported consistently in literature
[7,28,29].
Although all available survivors meeting the growth and
age criteria were invited to participate in this study and a
high percentage (85%) agreed to do so, our small study
group may be a quite selected sample not reflecting the
cognitive functioning of the average population of ALL
survivors. Because we have no information of pre-morbid
functioning of these patients, and since our study lacks a
control group, we can not exclude general or individual
detrimental effects of ALL-treatment. Further, the
observed high average IQ scores may be skewed due to the
Flynn effect, that is Dutch test norms of the WAIS were
published in 1970 and gains of IQ-points over time can
add up from 2 to 3 points per decade [30]. However, if we
adjust the mean high average IQ scores in the present
patient group for the Flynn effect, these scores would be
still in the normal range. This is in accordance with Von
der Weid et al. [6] who described normal cognitive out-
come in adolescent and young adult survivors of ALL.
These survivors, however, were treated with chemother-
apy alone. Since literature suggests different neurocogni-
tive outcome in children with ALL treated with or without
CNS irradiation and in view of our controversial findings
concerning scores of intellectual and specific neuropsy-
chological tests in adult survivors, the need for further
investigation of the very long term neurocognitive effects
of treatment of childhood ALL, with or without cranial
irradiation, in adult survivors is underlined.
In the present study IGF-I levels were used as expression of
neuroendocrine effects of growth hormone therapy and
were related to testscores. Mean IGF-I level increased in
the first year of treatment, decreased in the second year,
but remained higher than at pre-treatment. After one year
of GH treatment scores on tests measuring verbal short-
and long-term memory decreased as IGF-I levels
increased. After the second year of treatment the short-
and long-term memory scores increased to the levels at T1
as IGF-I decreased. Thus, with respect to memory, an
increase in IGF-I in the first year of treatment seems to be
associated with impaired memory performance, which
impairment seems to be counteracted by a reduced IGF-I
level. In addition, sustained attention was significantly
improved after the first and second treatment year, as IGF-
I was highly increased. The absence of a difference in
response on sustained attention between session 2 and 3
may be associated with the reduced IGF-I levels after one
year of GH treatment. All in all, the GH-induced IGF-I
increase in the first treatment year seems to impair specific
(verbal) memory functions, which conclusion may be
inferred from the observation that memory impairment is
halted when IGF-I levels are lowered. It may well be true
that the IGF-I increase in the fist year is too high to
improve verbal memory functions which even results in
an opposite effect, that is impairment of verbal memory.
An other possible explanation could be that IGF-1 sensi-
tivity of the brain is altered by prophylactic CRT.
Positive effects found in the present study concerns visual-
spatial long term memory and sustained attention, which
functions are improved after one year of treatment and
respectively tend to be or are still improved after the sec-
ond treatment year. Correlation analysis indicated that
the IGF-I increase in the first treatment year is associated
with an improvement of visual-spatial long term memory
at month 12 and 24 relative to baseline. No relation was
found between the increase in IGF-I during two years of
treatment and changes in visual-spatial long term mem-
ory. As perceptual skills play a role in both spatial long-
term memory and sustained attention, this result suggests
that especially cognitive perceptual performance after one
and two years of GH treatment are related to the IGF-I
increase in the first year. Indeed, a relationship between
IGF-I levels and perceptual functions has been reported by
Mean IGF-I levels (nmol/l) and Verbal short term memory  scores (15 Word Test – immediate recall) prior to start of  GH treatment and after 12 and 24 months Figure 2
Mean IGF-I levels (nmol/l) and Verbal short term 
memory scores (15 Word Test – immediate recall) 
prior to start of GH treatment and after 12 and 24 
months.
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Aleman et al. [31]. In healthy male subjects (mean age of
69 years) higher IGF-1 levels were associated to better
scores on the Digit Symbol Substitution test (W.A.I.S.),
which test measures perceptual-motor functions and vis-
ual-spatial memory. As visual-spatial memory plays an
important role in the performance on the Rey complex fig-
ure test it may well be true that a substantial increase in
IGF-I may enhance visual-spatial (memory) functions.
We conclude that the present results show some beneficial
effects of GH treatment on visual-spatial (long term)
memory functions and attention in ALL survivors, while
verbal memory functions are negatively affected.
Conclusion
This study is the first presenting data about the neurocog-
nitive functioning of adult survivors of childhood leukae-
mia in relation to GH treatment. Since most participants
were treated with regimens including prophylactic cranial
irradiation, the finding that these survivors showed at
least an average level of intellectual functioning and neu-
ropsychological test scores in the normal range is unex-
pected and asks for further research. The present finding
that GH treatment has negative effects on verbal memory
and positive effects on visual-spatial memory and atten-
tion warrants similar studies in other groups of ALL survi-
vors. However, because of the unexpected high level of
cognitive functioning and low levels of IGF-1 of our sam-
ple care is needed to generalize our results to the ALL pop-
ulation as a whole. In addition, the average baseline levels
of cognitive functioning in our study group and positive
effects of GH treatment on two particular neuropsycho-
logical tests while effects on other tests were absent or neg-
ative, questions clinical relevance. Further, because of
these different effects of GH treatment on the neuropsy-
chological tests observed positive effects may result from
chance. In addition to the possibility that GH treatment
may help ALL survivors with worse intellectual function-
ing, a lower dose of GH may be more effective as an
increase too high of IGF-I may adversely affect verbal
memory performance. However, it will be difficult to pre-
cisely determine the effective dose to improve verbal as
well as visual cognitive functions, because a dose too low
may in turn not affect visual memory and attention.
All in all, conclusions from studies in younger groups of
survivors on neurocognitive toxicity of leukemia treat-
ment, may not hold in all cases of young adult survivors.
In addition, as has been described before in growth hor-
mone deficient adults [17-19], the results of the present
study suggest that relationships between GH therapy and
aspects of neuropsychological functioning are strongly
dependent on IGF-I levels. For theoretical and clinical rea-
sons replication of this study and further research into
these complex relationships is strongly recommended.
Based on the present results, we conclude that more
knowledge is needed before GH treatment to enhance
cognitive functions in ALL survivors may be recom-
mended.
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